Zyprexa

Riik: Euroopa Liit

keel: inglise

Allikas: EMA (European Medicines Agency)

Osta kohe

Infovoldik Infovoldik (PIL)
26-02-2024
Toote omadused Toote omadused (SPC)
26-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande (PAR)
03-07-2013

Toimeaine:

olanzapine

Saadav alates:

Eli Lilly Nederland B.V.

ATC kood:

N05AH03

INN (Rahvusvaheline Nimetus):

olanzapine

Terapeutiline rühm:

Psycholeptics

Terapeutiline ala:

Schizophrenia; Bipolar Disorder

Näidustused:

Coated tabletsAdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.InjectionAdultsZyprexa powder for solution for injection is indicated for the rapid control of agitation and disturbed behaviours in patients with schizophrenia or manic episode, when oral therapy is not appropriate. Treatment with Zyprexa powder for solution for injection should be discontinued and the use of oral olanzapine should be initiated as soon as clinically appropriate.

Toote kokkuvõte:

Revision: 42

Volitamisolek:

Authorised

Loa andmise kuupäev:

1996-09-27

Infovoldik

                                60
B. PACKAGE LEAFLET
61
PACKAGE LEAFLET: INFORMATION FOR THE USER
ZYPREXA 2.5 MG COATED TABLETS
ZYPREXA 5 MG COATED TABLETS
ZYPREXA 7.5 MG COATED TABLETS
ZYPREXA 10 MG COATED TABLETS
ZYPREXA 15 MG COATED TABLETS
ZYPREXA 20 MG COATED TABLETS
olanzapine
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
•
If you get any side effects talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What ZYPREXA is and what it is used for
2.
What you need to know before you take ZYPREXA
3.
How to take ZYPREXA
4.
Possible side effects
5.
How to store ZYPREXA
6.
Contents of the pack and other information
1.
WHAT ZYPREXA IS AND WHAT IT IS USED FOR
ZYPREXA contains the active substance olanzapine. ZYPREXA belongs to a
group of medicines
called antipsychotics and is used to treat the following conditions:
•
Schizophrenia, a disease with symptoms such as hearing, seeing or
sensing things which are not
there, mistaken beliefs, unusual suspiciousness, and becoming
withdrawn. People with this
disease may also feel depressed, anxious or tense.
•
Moderate to severe manic episodes, a condition with symptoms of
excitement or euphoria.
ZYPREXA has been shown to prevent recurrence of these symptoms in
patients with bipolar disorder
whose manic episode has responded to olanzapine treatment.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE ZYPREXA
_ _
DO NOT TAKE ZYPREXA
•
If you are allergic (hypersensitive) to olanzapine or any of the other
ingredients of this medicine
(listed in section 6).
An allergic reaction may be recognised as a rash, itching, a swollen
face,
swollen lips or shortness of breath. If this 
                                
                                Lugege kogu dokumenti
                                
                            

Toote omadused

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
ZYPREXA 2.5 mg coated tablets
ZYPREXA 5 mg coated tablets
ZYPREXA 7.5 mg coated tablets
ZYPREXA 10 mg coated tablets
ZYPREXA 15 mg coated tablets
ZYPREXA 20 mg coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ZYPREXA 2.5 mg coated tablets
Each coated tablet contains 2.5 mg olanzapine.
Excipient with known effect: Each coated tablet contains 102 mg
lactose monohydrate.
ZYPREXA 5 mg coated tablets
Each coated tablet contains 5 mg olanzapine.
Excipient with known effect: Each coated tablet contains 156 mg
lactose monohydrate.
ZYPREXA 7.5 mg coated tablets
Each coated tablet contains 7.5 mg olanzapine.
Excipient with known effect: Each coated tablet contains 234 mg
lactose monohydrate.
ZYPREXA 10 mg coated tablets
Each coated tablet contains 10 mg olanzapine.
Excipient with known effect: Each coated tablet contains 312 mg
lactose monohydrate.
ZYPREXA 15 mg coated tablets
Each coated tablet contains 15 mg olanzapine.
Excipient with known effect: Each coated tablet contains 178 mg
lactose monohydrate.
ZYPREXA 20 mg coated tablets
Each coated tablet contains 20 mg olanzapine.
Excipient with known effect: Each coated tablet conatins 238 mg
lactose monohydrate.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Coated tablet
ZYPREXA 2.5 mg coated tablets
Round, white, coated tablets
_ _
imprinted with “LILLY” and a numeric identicode “4112”.
ZYPREXA 5 mg coated tablets
Round, white, coated tablets
_ _
imprinted with “LILLY” and a numeric identicode “4115”.
ZYPREXA 7.5 mg coated tablets
Round, white, coated tablets
_ _
imprinted with “LILLY” and a numeric identicode “4116”.
3
ZYPREXA 10 mg coated tablets
Round, white, coated tablets
_ _
imprinted with “LILLY” and a numeric identicode “4117”.
ZYPREXA 15 mg coated tablets
Elliptical, blue, coated tablets
_ _
debossed with “LILLY” and a numeric identicode “4415”.
ZYPREXA 20 mg coated tablets
Pink, elliptical, coated tablets
_ 
                                
                                Lugege kogu dokumenti
                                
                            

Dokumendid teistes keeltes

Infovoldik Infovoldik bulgaaria 26-02-2024
Toote omadused Toote omadused bulgaaria 26-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande bulgaaria 03-07-2013
Infovoldik Infovoldik hispaania 26-02-2024
Toote omadused Toote omadused hispaania 26-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande hispaania 03-07-2013
Infovoldik Infovoldik tšehhi 26-02-2024
Toote omadused Toote omadused tšehhi 26-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande tšehhi 03-07-2013
Infovoldik Infovoldik taani 26-02-2024
Toote omadused Toote omadused taani 26-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande taani 03-07-2013
Infovoldik Infovoldik saksa 26-02-2024
Toote omadused Toote omadused saksa 26-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande saksa 03-07-2013
Infovoldik Infovoldik eesti 26-02-2024
Toote omadused Toote omadused eesti 26-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande eesti 03-07-2013
Infovoldik Infovoldik kreeka 26-02-2024
Toote omadused Toote omadused kreeka 26-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande kreeka 03-07-2013
Infovoldik Infovoldik prantsuse 26-02-2024
Toote omadused Toote omadused prantsuse 26-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande prantsuse 03-07-2013
Infovoldik Infovoldik itaalia 26-02-2024
Toote omadused Toote omadused itaalia 26-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande itaalia 03-07-2013
Infovoldik Infovoldik läti 26-02-2024
Toote omadused Toote omadused läti 26-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande läti 03-07-2013
Infovoldik Infovoldik leedu 26-02-2024
Toote omadused Toote omadused leedu 26-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande leedu 03-07-2013
Infovoldik Infovoldik ungari 26-02-2024
Toote omadused Toote omadused ungari 26-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande ungari 03-07-2013
Infovoldik Infovoldik malta 26-02-2024
Toote omadused Toote omadused malta 26-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande malta 03-07-2013
Infovoldik Infovoldik hollandi 26-02-2024
Toote omadused Toote omadused hollandi 26-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande hollandi 03-07-2013
Infovoldik Infovoldik poola 26-02-2024
Toote omadused Toote omadused poola 26-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande poola 03-07-2013
Infovoldik Infovoldik portugali 26-02-2024
Toote omadused Toote omadused portugali 26-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande portugali 03-07-2013
Infovoldik Infovoldik rumeenia 26-02-2024
Toote omadused Toote omadused rumeenia 26-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande rumeenia 03-07-2013
Infovoldik Infovoldik slovaki 26-02-2024
Toote omadused Toote omadused slovaki 26-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande slovaki 03-07-2013
Infovoldik Infovoldik sloveeni 26-02-2024
Toote omadused Toote omadused sloveeni 26-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande sloveeni 03-07-2013
Infovoldik Infovoldik soome 26-02-2024
Toote omadused Toote omadused soome 26-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande soome 03-07-2013
Infovoldik Infovoldik rootsi 26-02-2024
Toote omadused Toote omadused rootsi 26-02-2024
Avaliku hindamisaruande Avaliku hindamisaruande rootsi 03-07-2013
Infovoldik Infovoldik norra 26-02-2024
Toote omadused Toote omadused norra 26-02-2024
Infovoldik Infovoldik islandi 26-02-2024
Toote omadused Toote omadused islandi 26-02-2024
Infovoldik Infovoldik horvaadi 26-02-2024
Toote omadused Toote omadused horvaadi 26-02-2024

Otsige selle tootega seotud teateid

Vaadake dokumentide ajalugu